Clinical

Dataset Information

0

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors


ABSTRACT: This is a Phase 1b/2, multi-center, open label umbrella study of patients ≥12 years of age with recurrent, progressive, or refractory melanoma or other solid tumors with alterations in the key proteins of the RAS/RAF/MEK/ERK pathway, referred to as the MAPK pathway.

DISEASE(S): Raf Mutation,Carcinoma,Spitzoid Malignant Melanoma,Craf Fusion,Colorectal Cancer,Non Small Cell Lung Cancer,Mek Mutation,Craf Gene Amplification,Bladder Urothelial Carcinoma,Non-small Cell Adenocarcinoma,Craf Gene Fusion,Carcinoma, Acinar Cell,Pancreatic Neoplasms,Astrocytoma,Pancreatic Acinar Carcinoma,Spitzoid Melanoma,Raf1 Gene Fusion,Solid Tumor,Melanoma,Ras Mutation,Bladder Cancer,Braf Gene Fusion,Pilocytic Astrocytoma, Adult,Raf1 Gene Amplification,Thyroid Cancer, Papillary,Pilocytic Astrocytoma,Map Kinase Family Gene Mutation,Raf1 Fusion,Braf Fusion

PROVIDER: 2385126 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2024-10-04 | GSE273721 | GEO
2013-07-07 | E-GEOD-5481 | biostudies-arrayexpress
2021-06-06 | GSE158609 | GEO
2021-06-06 | GSE158608 | GEO
2021-06-06 | GSE158607 | GEO
2024-09-02 | BIOMD0000000666 | BioModels
2013-07-07 | GSE5481 | GEO
2016-11-21 | GSE75078 | GEO
2015-03-11 | PXD000528 | Pride
2023-10-24 | PXD036261 | Pride